The U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older. "Older adults, ...
In prior studies, it has been demonstrated that the requirement for mechanical ventilation, the existence of a co-respiratory infection, and the duration of hospital stay increase the risk of RSV-related mortality [31, 36,37,38]. However, our study revealed that death from RSV infection was ...
After multivariate analysis, age >60 years, symptoms and imaging evidence of lower respiratory tract infection (LRTI) were associated with oxygen requirement (Figure 1A); similar results were observed in an analysis of the lung transplant cohort only. Risk factors on multivariate analysis for ...
RSV infection contributes to a tremendous disease burden in older adults2 and children aged ≤2 years, particularly infants under 6 months of age3, posing a 14-fold higher risk of severe pneumonia in children4. In 2019, RSV was responsible for approximately 33.0 million ARIs episodes, 3.6 ...
Supplemental oxygen requirement and mortality were also higher among children with lower vs higher gestational age [5], [6]. Recently, RSV has also become recognized as a major contributor to respiratory illnesses among adults [7]. Although most cases reported in adults manifest as mild upper ...
Children with severe bronchiolitis experience a high protein turnover, and higher protein intake have been shown to significantly improve nitrogen balance. More recent pediatric intensive care unit (PICU) guidelines have suggested that 1.5/kg/day may be the minimum protein requirement and that higher ...
The mortality rate was substan- tial (12.1%), and age, comorbidity burden, and frailty were associated with a higher risk for adverse clinical outcomes. Conclusions Older adults are at higher risk for complications from influenza and RSV coinfections, especially those ...
Treatment options for RSV infection include a monoclonal antibody against the F protein of RSV. The high costs associated with such monoclonal antibodies and the requirement for administration in a hospital setting; preclude their use for prophylaxis in the at-risk population at large scale. Thus, ...
Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associated with the requirement for dosing throughout the RSV season makes its use impractical for all infants. We describe the development of a monoclonal antibody as potential RSV prophylaxis ...
Even so, the invention does not require the boundaries to be known with absolute precision, as the only basic requirement for the invention is that the coiled-coil domain should function in a way that allows the polypeptide to oligomerize with other coiled-coil domains without destroying the ...